Abstract: A hematology control composition and method of making the composition is provided. The control employs a plurality of components including a synthetic plasma component, a red blood cell component, a platelet component and a leukocyte component. The leukocyte component includes at least one subpopulation having particles derived from other than white blood cells.
Abstract: The present invention provides a method for preparing cells for use in a hematology blood control. The preparation steps, namely the use of cross-linking agents such as aldehydes, involve a step-wise process starting with very low concentrations of a cross-linking agent. Successive fixations involve an increase in the concentration of cross-linking agent.
Abstract: The control of the present invention involves a gentle chemical removal of red cells, leaving an intact white cell preparation. The preservation steps, namely the use of cross-linking agents as aldehydes, involve a step-wise process starting with very low concentrations of a cross-linking agent. The fixation part of the process outlined in this disclosure has also been applied to non-mammalian blood cells and therefor would appear to be a universal procedure for preparing all types of vertebrate blood cells.
Abstract: A three-phase suspension suitable for use as an erythrocyte sedimentation rate (ESR) control having the following three components: (1) a synthetic plasma base, (2) an aggregating agent such as a high molecular weight polymer or combination of high molecular weight polymers, and (3) chemically fixed mammalian red blood cells. The control is designed to allow the user to monitor the accuracy and precision of analytical methods for determining the sedimentation rate of human erythrocytes in whole blood specimens. Chemical fixing of the red blood cells provides the ESR control with the capability of providing useful results in the presence of citrate and/or saline.
Type:
Grant
Filed:
October 12, 1999
Date of Patent:
January 29, 2002
Assignees:
Streck Laboratories, Inc., Hematronix Inc.
Abstract: A three-phase suspension suitable for use as an erythrocyte sedimentation rate control having the following three components: (1) a synthetic plasma base, (2) a high molecular weight polymer, and (3) mammalian red blood cells. The control is designed to allow the user to monitor the accuracy and precision of analytical methods for determining the sedimentation rate of human erythrocytes in whole blood specimens.
Type:
Grant
Filed:
October 12, 1999
Date of Patent:
December 18, 2001
Assignees:
Streak Laboratories, Inc., Hematronix Inc.
Abstract: A composition and a method for using the composition for manipulating the electronic and optical properties of biological particles are disclosed. The composition generally has a hypotonic buffering solution, a polyhydroxy alcohol, a stabilizing agent, and, in some applications, a non-ionic surfactant. By varying the relative concentrations of these components and by adjusting the timing of their combination and interaction, the composition and method allow for the alteration of the electronic and optical properties of the particles to achieve target values for the properties. In one particularly advantageous application, the composition and method of the invention allow for the creation of selected analogs for the subpopulations of human leukocytes from a single biological particle for use as a control product in differentiating particle analyzers.
Type:
Grant
Filed:
June 16, 1997
Date of Patent:
November 14, 2000
Assignee:
Hematronix, Inc.
Inventors:
Franklin J. Carver, James D. Lapicola, Lorraine A. Granier
Abstract: A three-phase suspension suitable for use as an erythrocyte sedimentation rate control having the following three components: (1) a synthetic plasma base, (2) a high molecular weight polymer, and (3) mammalian red blood cells. The control is designed to allow the user to monitor the accuracy and precision of analytical methods for determining the sedimentation rate of human erythrocytes in whole blood specimens.
Type:
Grant
Filed:
March 22, 1999
Date of Patent:
April 18, 2000
Assignees:
Streck Laboratories, Inc., Hematronix, Inc.
Abstract: A three-phase suspension suitable for use as an erythrocyte sedimentation rate (ESR) control having the following three components: (1) a synthetic plasma base, (2) an aggregating agent such as a high molecular weight polymer or combination of high molecular weight polymers, and (3) chemically fixed mammalian red blood cells. The control is designed to allow the user to monitor the accuracy and precision of analytical methods for determining the sedimentation rate of human erythrocytes in whole blood specimens. Chemical fixing of the red blood cells provides the ESR control with the capability of providing useful results in the presence of citrate and/or saline.
Type:
Grant
Filed:
April 20, 1999
Date of Patent:
January 25, 2000
Assignees:
Streck Laboratories, Inc., Hematronix, Inc.